MAIA under the microscope — bringing trial design into focus

Research output: Contribution to journalArticle

Abstract

Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hand

ASJC Scopus subject areas

  • Oncology

Cite this

@article{a7bc11ec357b414bbac67e97062f9ff7,
title = "MAIA under the microscope — bringing trial design into focus",
abstract = "Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.",
author = "Prashant Kapoor and Rajkumar, {S Vincent}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-019-0198-0",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - MAIA under the microscope — bringing trial design into focus

AU - Kapoor, Prashant

AU - Rajkumar, S Vincent

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.

AB - Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85062700204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062700204&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0198-0

DO - 10.1038/s41571-019-0198-0

M3 - Article

C2 - 30850718

AN - SCOPUS:85062700204

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -